title: Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
abstract: OBJECTIVE
  Carboplatin-associated hypersensitivity is increasingly recognized as a potentially serious toxicity when this agent is administered for more than six total cycles.
  
  
  METHODS
  Our group has used a predictive skin test in women with gynecologic cancers who have previously received more than six cumulative cycles of platinum-based chemotherapy. Thirty minutes before all subsequent carboplatin courses, a 0.02-mL aliquot from the solution prepared for treatment is injected intradermally. A positive test is considered to be a > or = 5-mm wheal, with a surrounding flare.
  
  
  RESULTS
  From October 1998 through March 2003, 126 patients received a total of 717 carboplatin skin tests (median per patient, four tests; range, one to 54 tests). Of the 668 negative tests (93% of the total performed), 10 were associated with evidence of carboplatin hypersensitivity (1.5% false-negative rate; 95% CI, 0.6% to 2.4%), none of which were severe (eg, dyspnea, hypotension, cardiac/respiratory compromise). Of the 41 positive tests, the decision was made to not deliver the drug to 32 patients, although seven women ultimately underwent a future attempt at re-treatment with a platinum agent using a desensitization program. In seven episodes where patients received the carboplatin despite the finding of a positive test, six were associated with the development of symptoms of anaphylaxis (none severe).
  
  
  CONCLUSIONS
  A negative carboplatin skin test seems to predict with reasonable reliability for the absence of a severe hypersensitivity reaction with the subsequent drug infusion. The implications of a positive test remain less certain, but limited experience with continued treatment suggests this approach must be undertaken with considerable caution.
authors.affiliation: Department of Hematology/Medical Oncology (R-35), the Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA. markmam@ccf.org
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
authors.forename: Kristine
authors.initials: K
authors.lastname: Zanotti
authors.forename: Gertrude
authors.initials: G
authors.lastname: Peterson
authors.forename: Barbara
authors.initials: B
authors.lastname: Kulp
authors.forename: Kenneth
authors.initials: K
authors.lastname: Webster
authors.forename: Jerome
authors.initials: J
authors.lastname: Belinson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016190:Carboplatin / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011237:Predictive Value of Tests; D012882:Skin Tests
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin